Review
PDF EndNote BibTex RIS Cite

Temporomandibular Rahatsızlıkların Tedavisinde Botulinum Toksin Kullanımı

Year 2022, Volume 6, Issue 1, 46 - 57, 22.06.2022
https://doi.org/10.29228/erd.26

Abstract

Temporomandibular rahatsızlıklar (TMR), temporomandibular eklemler, çiğneme kasları ve tüm ilişkili dokuları kapsayan bir grup rahatsızlık olarak tanımlanmıştır. TMR’si olan hastalarda eklem ve çiğneme kaslarında hassasiyet ve ağrı, ağız açmada kısıtlılık, eklem sesleri gibi semptomlar görülür. TMR tedavisi genellikle multidisipliner yaklaşım gerektirir. Tedavide öncelik geri dönüşümsüz etkileri olmayan konservatif tedavi seçenekleri olmalıdır. Günümüzde bu tedavi seçeneklerinden biri olan Botulinum toksin (BoNT) uygulanması diş hekimliğinin birçok alanıyla birlikte çeşitli TMR'lerin tedavisinde de kullanılmaktadır. BoNT, nöromusküler kavşakta asetilkolin salınımını inhibe eden ve hedef kasta kontraksiyonu engelleyen bir nörotoksindir. TMR tedavisinde BoNT, çeşitli temporomandibular hastalık ve semptomlara yol açan kas gerginliğini azaltmak amacıyla uygulanmaktadır. Bu derlemede, BoNT’in TMR tedavisindeki yeri, uygulama tekniği ve semptomlar üzerindeki etkisi literatürdeki çalışmalar ışığında değerlendirilmektedir.

References

  • 1. Altaweel AA, Elsayed SAH, Baı̇omy AABA, Abdelsadek SE, Hyder AA. Extraoral Versus Intraoral Botulinum Toxin Type A Injection for Management of Temporomandibular Joint Disc Displacement With Reduction. J Craniofac Surg, 2019; 30(7): 2149–53.
  • 2. Aquilina P, Vickers R, McKellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral Maxillofac Surg. 2004; 42: 272-273.
  • 3. Arinci A, Güven E, Yazar M, Başaran K, Keklik B. Effect of injection of botulinum toxin on lateral pterygoid muscle used together with the arthroscopy in patients with anterior disk displacement of the temporomandibular joint. Kulak Burun Bogaz Ihtis Derg. 2009;19(3):122-9.
  • 4. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-70.
  • 5. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 ;30(7):793-803.
  • 6. Bakheı̇t, AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Current Drug Safety. 2006; 1(3): 271–9.
  • 7. Bakke M, Møller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 693-700.
  • 8. Barnes M. Botulinum toxin- mechanisms of action and clinical use in spasticity. J Rehabil Med. 2003; 35(0): 56–9.
  • 9. Baumann L, Black L. Botulinum toxin type B (Myobloc). Dermatol Surg. 2003; 29(5): 496–500.
  • 10. Bhogal PS, Hutton A, Monaghan A. Review of the current uses of Botox for dentally-related procedures. Dental Update. 2006; 33(3): 165-8.
  • 11. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Südhof TC, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem. 1994; 269(3): 1617-20.
  • 12. Bottemly I. Comparing Neuretoxins: Botox, Dysport, Jeuveau and Xeomin. Erişim Tarihi (14.3.2022) https://aedit.com/aedition/comparing-neurotoxin-botulinum-type-a-injections-botox-dysport-jeuveau-xeomin
  • 13. Brin MF, Blitzer A, Herman S, Steward C. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin A. In therapy with botulinum toxin. 1994; 19: 429–35.
  • 14. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J. Physiol. 1949;109: 10-24.
  • 15. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with botulinum A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.
  • 16. Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rimabotulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33:304-18.
  • 17. Clark GT, Stiles A, Lockerman LZ, Gross SG. A critical review of the use of botulinum toxin in orofacial pain disorders. Dent Clin North Am. 2007; 51:245–61.
  • 18. Connelly ST, Myung J, Gupta R, Tartaglia GM, Gizdulich A, Yang J, Silva R. Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain? Int J Oral Maxillofac Surg. 2017;46(3):322-7.
  • 19. Dashtipour K, Pedouim F. Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile. Semin Neurol. 2016;36(1):29-33. 20. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Garcia RCMR, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017; 21(3):727–734.
  • 21. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-8.
  • 22. Emara AS, Faramawey MI, Hassaan MA, Hakam MM. Botulinum toxin injection for management of temporomandibular joint clicking. Int J Oral Maxillofac Surg. 2013;42(6):759-64.
  • 23. Erbguth‭ ‬FJ,‭ ‬Naumann‭ ‬M.‭ ‬Historical‭ ‬aspects‭ ‬of‭ ‬botulinum toxin:‭ ‬Justinus‭ ‬Kerner‭ ‬(1786–1862)‭ ‬and‭ ‬the‭ ‬‘sausage‭ ‬poison’. Neurology.‭ ‬1999;53:1850–3.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 24. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152(9):1988-96.
  • 25. Freund B, Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health. 1998 Feb;88(2):32-7.
  • 26. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000 ;38(5):466-71.
  • 27. Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg. 2010;48(4):281-4.
  • 28. Gezer AI, Levendoğlu F. Temporomandibular Eklem Rahatsızlıklarının Sınıflandırılması, Tanı ve Tedavisi, Genel Tıp Derg. 2016;26(1):34-40.
  • 29. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008; 26(2):126-35.
  • 30. Guo BL, Zheng CX, Sui BD, Li YQ, Wang YY, Yang YL. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013; 71:134-9.
  • 31. Güreser G. Temporomandibular Eklem Hastalıkları. Fiziksel Tıp. 2003; 6(2):37-45.
  • 32. Hellman A, Torres-Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord. 2015; 8:82-91.
  • 33. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2 Pt 1):249-59.
  • 34. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104: e1-11.
  • 35. Isaac AM, Moss CE, Whear NM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type-A. Br J Oral Maxillofac Surg. 2000; 38:571–2.
  • 36. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-45.
  • 37. Jensen R. Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies. Cephalalgia.1999;19:602–21.
  • 38. Juniper RP. Temporomandibular joint dysfunction: a theory based upon electromyographic studies of the lateral pterygoid muscle. Br J Oral Maxillofac Surg. 1984;22(1):1-8.
  • 39. Karacalar A, Yilmaz N, Bilgici A, Baş B, Akan H. Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience. J Craniofac Surg. 2005;16(3):476-81.
  • 40. Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study. Niger J Clin Pract. 2021;24(3):412-417.
  • 41. Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016 Jan 28;38(1):5.
  • 42. Kocaelli H, Çakarer S, Yaltırık M. Botulinum Toksin (Btx) ve klinik kullanımı/BotulinumToxin (Btx) And Clinical Usage. J Istanbul Univ Fac Dent. 2012; 38(3-4): 37-43.
  • 43. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008; 66: 1644–51.
  • 44. Mahajan‭ ‬ST, Brubaker‭ ‬L.‭ ‬Botulinum‭ ‬toxin:‭ ‬from life-threatening‭ ‬disease‭ ‬to‭ ‬novel‭ ‬medical‭ ‬therapy.‭ ‬Am‭ ‬J‭ ‬Obstet‭ ‬Gynecol.2007;196:7–15.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 45. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010;39(3):197-207.
  • 46. Monroy PG, da Fonseca MA. The use of botulinum toxin-A in the treatment of severe bruxism in a patient with autism: a case report. Spec Care Dentist. 2006;26(1):37-9.
  • 47. Montecucco C, Schiavo G, Rossetto O. The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol Suppl. 1996; 18:342-54.
  • 48. Moore AP, Wood GD. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J. 1997;183(11-12):415-7.
  • 49. Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000 Jan 15;320(7228):161-5.
  • 50. Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2011;55(1):105-20.
  • 51. Okeson JP. Management of Temporomandibular Disorders and Occlusion. 8th ed. Elsevier;2015.p. 5-15,109,110,261-65.
  • 52. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism. Neurology. 2018; 90(7): e559–64. 53. Orlova, O. Botulinum Toxin Therapy for Bruxism. Dirk Dressler, Eckart Altenmüller, Joachim K.Krauss editors. Treatment of Dystonia. Cambridge University Press; 2018. p.182–184.
  • 54. Patel J, Cardoso JA, Mehta S. A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. British Dental Journal. 2019; 226(9), 667–72.
  • 55. Pons M, Meyer C, Euvrard E, Weber E, Sigaux N, Louvrier A. MR-guided navigation for botulinum toxin injection in the lateral pterygoid muscle. First results in the treatment of temporomandibular joint disorders. J Stomatol Oral Maxillofac Surg. 2019;120(3):188-195.
  • 56. Sakaguchi‭ ‬G.‭ ‬Clostridium‭ ‬botulinum‭ ‬toxins.‭ ‬Pharmacol‭ ‬Ther. 1982; 19:165–94‬‬‬‬‬‬‬‬‬‬‬‬.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 57. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18(6):198-203.
  • 58. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus.Trans Am Ophthalmol Soc. 1981;79:734-770.
  • 59. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(6):119-24.
  • 60. Sipahi Calis A, Colakoglu Z, Gunbay S. The use of botulinum toxin-a in the treatment of muscular temporomandibular joint disorders. J Stomatol Oral Maxillofac Surg. 2019 Sep;120(4):322-325.
  • 61. Skármeta NP, Espinoza-Mellado P, Chana P. Orofacial Dystonia and Other Oromandibular Movement Disorders. Dystonia - Different Prospects 2018;10-36.
  • 62. Smuts JA, Baker MK, Smuts HM, Stassen JR, Rossouw E, Barnard PW. et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999;6(4):99–102.
  • 63. Soğancı G, Yağcı F. Diş Hekimliğinde Botoks: Derleme. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2016; 26(2): 0-0.
  • 64. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007; 13(3): 253-60.
  • 65. Stephens MD, Talbot JC, Routledge PA. Detection Of New Adverse Drug Reactions. 4th ed. Groves Dictionaries, Incorporated London; 1998. p.32–44.
  • 66. Sunil Dutt C, Ramnani P, Thakur D, Pandit M. Botulinum toxin in the treatment of muscle specific Oro-facial pain: a literature review. J Maxillofac Oral Surg. 2015 Jun;14(2):171-5.
  • 67. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015; 33(4):291-8.
  • 68. Tintner R, Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 343-350.
  • 69. Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des. 2009;15(31):3671-80.
  • 70. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200.
  • 71. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990 Jun;53(6):530.
  • 72. Villa S, Raoul G, Machuron F, Ferri J, Nicot R. Improvement in quality of life after botulinum toxin injection for temporomandibular disorder. J Stomatol Oral Maxillofac Surg. 2019 ;120(1):2-6.
  • 73. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61(7):774-8.
  • 74. Yengin E. Temporomandibular Rahatsızlıklarda Teşhis ve Tedavi. İstanbul: İstanbul Üniversitesi Diş Hekimliği Fakültesi Yayınları;2000.
  • 75. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9.
  • 76. Yoshida K. Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins (Basel). 2018;10(5):174.
  • 77. Ziegler CM, Haag C, Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003 Mar;7(1):52-5.

Use of Botulinum Toxin In The Treatment of Temporomandibular Disorders

Year 2022, Volume 6, Issue 1, 46 - 57, 22.06.2022
https://doi.org/10.29228/erd.26

Abstract

Temporomandibular disorder (TMD) is a term used to describe disorders that involve the temporomandibular joint, the masticatory muscles and associated structures. Patients with TMD have symptoms such as tenderness and pain in the joints and masticatory muscles, limitation in mouth opening, and joint sounds. TMD treatment usually requires a multidisciplinary approach and reversible conservative treatment options should be the first choice. Botulinum toxin (BoNT) injection, which is one of these treatment options, is used in many areas of dentistry, as well as in various TMD treatments. BoNT is a neurotoxin that inhibits the release of acetylcholine at the neuromuscular junction and inhibits contraction of the target muscle. In the treatment of TMD, BoNT is applied to reduce muscle tension that causes various temporomandibular diseases and symptoms. In this review, the place of BoNT injection in TMD treatment, its application technique and its effect on symptoms are evaluated in the light of literature.

References

  • 1. Altaweel AA, Elsayed SAH, Baı̇omy AABA, Abdelsadek SE, Hyder AA. Extraoral Versus Intraoral Botulinum Toxin Type A Injection for Management of Temporomandibular Joint Disc Displacement With Reduction. J Craniofac Surg, 2019; 30(7): 2149–53.
  • 2. Aquilina P, Vickers R, McKellar G. Reduction of a chronic bilateral temporomandibular joint dislocation with intermaxillary fixation and botulinum toxin A. Br J Oral Maxillofac Surg. 2004; 42: 272-273.
  • 3. Arinci A, Güven E, Yazar M, Başaran K, Keklik B. Effect of injection of botulinum toxin on lateral pterygoid muscle used together with the arthroscopy in patients with anterior disk displacement of the temporomandibular joint. Kulak Burun Bogaz Ihtis Derg. 2009;19(3):122-9.
  • 4. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management. JAMA. 2001;285(8):1059-70.
  • 5. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010 ;30(7):793-803.
  • 6. Bakheı̇t, AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Current Drug Safety. 2006; 1(3): 271–9.
  • 7. Bakke M, Møller E, Werdelin LM, Dalager T, Kitai N, Kreiborg S. Treatment of severe temporomandibular joint clicking with botulinum toxin in the lateral pterygoid muscle in two cases of anterior disc displacement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 693-700.
  • 8. Barnes M. Botulinum toxin- mechanisms of action and clinical use in spasticity. J Rehabil Med. 2003; 35(0): 56–9.
  • 9. Baumann L, Black L. Botulinum toxin type B (Myobloc). Dermatol Surg. 2003; 29(5): 496–500.
  • 10. Bhogal PS, Hutton A, Monaghan A. Review of the current uses of Botox for dentally-related procedures. Dental Update. 2006; 33(3): 165-8.
  • 11. Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Südhof TC, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem. 1994; 269(3): 1617-20.
  • 12. Bottemly I. Comparing Neuretoxins: Botox, Dysport, Jeuveau and Xeomin. Erişim Tarihi (14.3.2022) https://aedit.com/aedition/comparing-neurotoxin-botulinum-type-a-injections-botox-dysport-jeuveau-xeomin
  • 13. Brin MF, Blitzer A, Herman S, Steward C. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin A. In therapy with botulinum toxin. 1994; 19: 429–35.
  • 14. Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J. Physiol. 1949;109: 10-24.
  • 15. Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with botulinum A exotoxin. J Dermatol Surg Oncol. 1992;18:17–21.
  • 16. Chen JJ, Dashtipour K. Abo-, inco-, ona-, and rimabotulinum toxins in clinical therapy: a primer. Pharmacotherapy. 2013;33:304-18.
  • 17. Clark GT, Stiles A, Lockerman LZ, Gross SG. A critical review of the use of botulinum toxin in orofacial pain disorders. Dent Clin North Am. 2007; 51:245–61.
  • 18. Connelly ST, Myung J, Gupta R, Tartaglia GM, Gizdulich A, Yang J, Silva R. Clinical outcomes of Botox injections for chronic temporomandibular disorders: do we understand how Botox works on muscle, pain, and the brain? Int J Oral Maxillofac Surg. 2017;46(3):322-7.
  • 19. Dashtipour K, Pedouim F. Botulinum Toxin: Preparations for Clinical Use, Immunogenicity, Side Effects, and Safety Profile. Semin Neurol. 2016;36(1):29-33. 20. De la Torre Canales G, Câmara-Souza MB, do Amaral CF, Garcia RCMR, Manfredini D. Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig. 2017; 21(3):727–734.
  • 21. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-8.
  • 22. Emara AS, Faramawey MI, Hassaan MA, Hakam MM. Botulinum toxin injection for management of temporomandibular joint clicking. Int J Oral Maxillofac Surg. 2013;42(6):759-64.
  • 23. Erbguth‭ ‬FJ,‭ ‬Naumann‭ ‬M.‭ ‬Historical‭ ‬aspects‭ ‬of‭ ‬botulinum toxin:‭ ‬Justinus‭ ‬Kerner‭ ‬(1786–1862)‭ ‬and‭ ‬the‭ ‬‘sausage‭ ‬poison’. Neurology.‭ ‬1999;53:1850–3.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 24. Ernberg M, Hedenberg-Magnusson B, List T, Svensson P. Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study. Pain. 2011;152(9):1988-96.
  • 25. Freund B, Schwartz M. The use of botulinum toxin for the treatment of temporomandibular disorder. Oral Health. 1998 Feb;88(2):32-7.
  • 26. Freund B, Schwartz M, Symington JM. Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg. 2000 ;38(5):466-71.
  • 27. Fu KY, Chen HM, Sun ZP, Zhang ZK, Ma XC. Long-term efficacy of botulinum toxin type A for the treatment of habitual dislocation of the temporomandibular joint. Br J Oral Maxillofac Surg. 2010;48(4):281-4.
  • 28. Gezer AI, Levendoğlu F. Temporomandibular Eklem Rahatsızlıklarının Sınıflandırılması, Tanı ve Tedavisi, Genel Tıp Derg. 2016;26(1):34-40.
  • 29. Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008; 26(2):126-35.
  • 30. Guo BL, Zheng CX, Sui BD, Li YQ, Wang YY, Yang YL. A closer look to botulinum neurotoxin type A-induced analgesia. Toxicon. 2013; 71:134-9.
  • 31. Güreser G. Temporomandibular Eklem Hastalıkları. Fiziksel Tıp. 2003; 6(2):37-45.
  • 32. Hellman A, Torres-Russotto D. Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord. 2015; 8:82-91.
  • 33. Huang W, Foster JA, Rogachefsky AS. Pharmacology of botulinum toxin. J Am Acad Dermatol. 2000;43(2 Pt 1):249-59.
  • 34. Ihde SK, Konstantinovic VS. The therapeutic use of botulinum toxin in cervical and maxillofacial conditions: an evidence-based review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104: e1-11.
  • 35. Isaac AM, Moss CE, Whear NM. Unilateral temporalis muscle hypertrophy managed with botulinum toxin type-A. Br J Oral Maxillofac Surg. 2000; 38:571–2.
  • 36. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA. 2012;307(16):1736-45.
  • 37. Jensen R. Pathophysiological mechanisms of tension-type headache: a review of epidemiological and experimental studies. Cephalalgia.1999;19:602–21.
  • 38. Juniper RP. Temporomandibular joint dysfunction: a theory based upon electromyographic studies of the lateral pterygoid muscle. Br J Oral Maxillofac Surg. 1984;22(1):1-8.
  • 39. Karacalar A, Yilmaz N, Bilgici A, Baş B, Akan H. Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience. J Craniofac Surg. 2005;16(3):476-81.
  • 40. Kaya DI, Ataoglu H. Botulinum toxin treatment of temporomandibular joint pain in patients with bruxism: A prospective and randomized clinical study. Niger J Clin Pract. 2021;24(3):412-417.
  • 41. Kim HS, Yun PY, Kim YK. A clinical evaluation of botulinum toxin-A injections in the temporomandibular disorder treatment. Maxillofac Plast Reconstr Surg. 2016 Jan 28;38(1):5.
  • 42. Kocaelli H, Çakarer S, Yaltırık M. Botulinum Toksin (Btx) ve klinik kullanımı/BotulinumToxin (Btx) And Clinical Usage. J Istanbul Univ Fac Dent. 2012; 38(3-4): 37-43.
  • 43. Kurtoglu C, Gur OH, Kurkcu M, Sertdemir Y, Guler-Uysal F, Uysal H. Effect of botulinum toxin A in myofascial pain patients with or without functional disc displacement. J Oral Maxillofac Surg. 2008; 66: 1644–51.
  • 44. Mahajan‭ ‬ST, Brubaker‭ ‬L.‭ ‬Botulinum‭ ‬toxin:‭ ‬from life-threatening‭ ‬disease‭ ‬to‭ ‬novel‭ ‬medical‭ ‬therapy.‭ ‬Am‭ ‬J‭ ‬Obstet‭ ‬Gynecol.2007;196:7–15.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 45. Majid OW. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int J Oral Maxillofac Surg. 2010;39(3):197-207.
  • 46. Monroy PG, da Fonseca MA. The use of botulinum toxin-A in the treatment of severe bruxism in a patient with autism: a case report. Spec Care Dentist. 2006;26(1):37-9.
  • 47. Montecucco C, Schiavo G, Rossetto O. The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol Suppl. 1996; 18:342-54.
  • 48. Moore AP, Wood GD. Medical treatment of recurrent temporomandibular joint dislocation using botulinum toxin A. Br Dent J. 1997;183(11-12):415-7.
  • 49. Münchau A, Bhatia KP. Uses of botulinum toxin injection in medicine today. BMJ. 2000 Jan 15;320(7228):161-5.
  • 50. Okeson JP, de Leeuw R. Differential diagnosis of temporomandibular disorders and other orofacial pain disorders. Dent Clin North Am. 2011;55(1):105-20.
  • 51. Okeson JP. Management of Temporomandibular Disorders and Occlusion. 8th ed. Elsevier;2015.p. 5-15,109,110,261-65.
  • 52. Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism. Neurology. 2018; 90(7): e559–64. 53. Orlova, O. Botulinum Toxin Therapy for Bruxism. Dirk Dressler, Eckart Altenmüller, Joachim K.Krauss editors. Treatment of Dystonia. Cambridge University Press; 2018. p.182–184.
  • 54. Patel J, Cardoso JA, Mehta S. A systematic review of botulinum toxin in the management of patients with temporomandibular disorders and bruxism. British Dental Journal. 2019; 226(9), 667–72.
  • 55. Pons M, Meyer C, Euvrard E, Weber E, Sigaux N, Louvrier A. MR-guided navigation for botulinum toxin injection in the lateral pterygoid muscle. First results in the treatment of temporomandibular joint disorders. J Stomatol Oral Maxillofac Surg. 2019;120(3):188-195.
  • 56. Sakaguchi‭ ‬G.‭ ‬Clostridium‭ ‬botulinum‭ ‬toxins.‭ ‬Pharmacol‭ ‬Ther. 1982; 19:165–94‬‬‬‬‬‬‬‬‬‬‬‬.‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬
  • 57. Schwartz M, Freund B. Treatment of temporomandibular disorders with botulinum toxin. Clin J Pain. 2002;18(6):198-203.
  • 58. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus.Trans Am Ophthalmol Soc. 1981;79:734-770.
  • 59. Setler PE. Therapeutic use of botulinum toxins: background and history. Clin J Pain. 2002;18(6):119-24.
  • 60. Sipahi Calis A, Colakoglu Z, Gunbay S. The use of botulinum toxin-a in the treatment of muscular temporomandibular joint disorders. J Stomatol Oral Maxillofac Surg. 2019 Sep;120(4):322-325.
  • 61. Skármeta NP, Espinoza-Mellado P, Chana P. Orofacial Dystonia and Other Oromandibular Movement Disorders. Dystonia - Different Prospects 2018;10-36.
  • 62. Smuts JA, Baker MK, Smuts HM, Stassen JR, Rossouw E, Barnard PW. et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999;6(4):99–102.
  • 63. Soğancı G, Yağcı F. Diş Hekimliğinde Botoks: Derleme. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi. 2016; 26(2): 0-0.
  • 64. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis. 2007; 13(3): 253-60.
  • 65. Stephens MD, Talbot JC, Routledge PA. Detection Of New Adverse Drug Reactions. 4th ed. Groves Dictionaries, Incorporated London; 1998. p.32–44.
  • 66. Sunil Dutt C, Ramnani P, Thakur D, Pandit M. Botulinum toxin in the treatment of muscle specific Oro-facial pain: a literature review. J Maxillofac Oral Surg. 2015 Jun;14(2):171-5.
  • 67. Tinastepe N, Küçük BB, Oral K. Botulinum toxin for the treatment of bruxism. Cranio. 2015; 33(4):291-8.
  • 68. Tintner R, Jankovic J. Botulinum toxin type A in the management of oromandibular dystonia and bruxism. Scientific and therapeutic aspects of botulinum toxin. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 343-350.
  • 69. Truong DD, Stenner A, Reichel G. Current clinical applications of botulinum toxin. Curr Pharm Des. 2009;15(31):3671-80.
  • 70. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg. 2001;54(3):197-200.
  • 71. Van Zandijcke M, Marchau MM. Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry. 1990 Jun;53(6):530.
  • 72. Villa S, Raoul G, Machuron F, Ferri J, Nicot R. Improvement in quality of life after botulinum toxin injection for temporomandibular disorder. J Stomatol Oral Maxillofac Surg. 2019 ;120(1):2-6.
  • 73. von Lindern JJ, Niederhagen B, Bergé S, Appel T. Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity. J Oral Maxillofac Surg. 2003;61(7):774-8.
  • 74. Yengin E. Temporomandibular Rahatsızlıklarda Teşhis ve Tedavi. İstanbul: İstanbul Üniversitesi Diş Hekimliği Fakültesi Yayınları;2000.
  • 75. Yiannakopoulou E. Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology. 2015;95(1-2):65-9.
  • 76. Yoshida K. Botulinum neurotoxin injection for the treatment of recurrent temporomandibular joint dislocation with and without neurogenic muscular hyperactivity. Toxins (Basel). 2018;10(5):174.
  • 77. Ziegler CM, Haag C, Mühling J. Treatment of recurrent temporomandibular joint dislocation with intramuscular botulinum toxin injection. Clin Oral Investig. 2003 Mar;7(1):52-5.

Details

Primary Language Turkish
Subjects Dental
Journal Section Reviews
Authors

Hatice Banu UYSAL ÖZEL> (Primary Author)
İstanbul Üniversitesi Diş Hekimliği Fakültesi Protetik Diş Tedavisi A.D. Çene Yüz Protezleri Bilim Dalı
0000-0003-1382-9670
Türkiye


Yılmaz Umut ASLAN>
MARMARA ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ
0000-0003-0500-7546
Türkiye


Erkan SANCAKLI>
İSTANBUL ÜNİVERSİTESİ, DİŞ HEKİMLİĞİ FAKÜLTESİ
0000-0002-5383-5314
Türkiye

Publication Date June 22, 2022
Published in Issue Year 2022, Volume 6, Issue 1

Cite

APA Uysal Özel, H. B. , Aslan, Y. U. & Sancaklı, E. (2022). Temporomandibular Rahatsızlıkların Tedavisinde Botulinum Toksin Kullanımı . European Journal of Research in Dentistry , 6 (1) , 46-57 . DOI: 10.29228/erd.26